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(33 MIs; 33 CABG/PTCAs; 11 strokes) with a total cost saving of
£332,512 (MI = £105,237; CABG/PTCA = £195,551; stroke =
£31,724). CONCLUSIONS: The estimated beneﬁt of treating to
an LDL-C target of <2.0 mmol/L rather than <3.0 mmol/L was
an additional 26 CV events avoided per 1000 patients with an
associated cost saving of £111,799.
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OBJECTIVES: A representative evaluation of CAD costs in
Poland including General Practitioners (GPs) and Specialists’ (S)
settings. METHODS: A representative sample of 2593 Polish
patients with conﬁrmed CAD (1977 patients under GP’s care,
616 patients under S care). A time horizon of the analysis was
12 month and a retrospective approach was applied. The study
estimated both direct medical and indirect costs resulted from
sick leaves, pensions and sickness beneﬁts. Unit costs were
obtained from available published data derived from the
National Health Fund and the Polish Social Insurance Institu-
tion. A prevalence based method using National Statistical
Ofﬁce data was used to estimate economic burden of CAD.
RESULTS: The distribution of total costs was similar in the
GPs’ and specialists’ settings. Hospitalisation and invasive treat-
ment constituted main direct medical costs’ drivers in both
conditions. The average direct medical cost per CAD patient
reached annually €1079.09. The average societal cost €1437.19
when the merely indirect costs related to the absence from
work (€358.10) was included. Average cost covering also indi-
rect cost related to the patients’ disability increased to the
€2254.17. The total average costs were signiﬁcantly (14.4%)
higher in Ss’ than in GPs’ settings. In accordance with the
lowest boundary estimate of CAD prevalence rate (2.9%), the
total, societal burden of CAD in Poland in 2005 amounted to
€2056.7 million. More than half of this cost (52.1%) was due
to the indirect cost, 69.5% of which resulted from patients’
disability. CONCLUSIONS: CAD imposes a high economic
burden for the third party payer as well as for Polish society.
Clearly, there is a need to develop and apply innovative, cost-
effective treatment strategies that will reduce the need for
hospitalisation and invasive treatment and may successfully be
implemented in the GPs’ practice.
PCV59
INPATIENT RESOURCE USE ASSOCIATED WITHTHE
TREATMENT OF SECONDARY ATRIAL FIBRILLATION
Spalding JR1, Exuzides A2,Adams S2, Colby C2, Noe L2
1Astellas Pharma US, Deerﬁeld, IL, USA, 2ICON Clinical Research,
San Francisco, CA, USA
OBJECTIVES: We estimated incremental inpatient costs and
length of stay (LOS) attributable to secondary atrial ﬁbrillation
(AF) in patients with and without cardiac predisposing factors to
document the economic burden of this disease. METHODS: We
extracted 2004–2005 discharges from Premier Perspective(tm),
the largest hospital database in the US, with a secondary AF
diagnosis and matched controls that had neither a primary nor a
secondary AF diagnosis. We matched on patient age, discharge
date, facility type and primary diagnosis category. We used
regression models to estimate the incremental inpatient costs and
LOS due to secondary AF. We adjusted for comorbidities, demo-
graphic and hospital-speciﬁc factors. We repeated this analysis
for patients without cardiac predisposing factors (i.e. mitral valve
disease, heart failure, non-AF cardiac operation, chest pain and
congestive artery disease). RESULTS: The estimated 5.4 million
secondary AF discharges in the US during 2004 and 2005 had an
adjusted average inpatient cost of $12,292. This cost was $3532
more than the adjusted average inpatient cost for controls
without AF (P < 0.0001). Patients with secondary AF had an
adjusted average LOS of 7.8 days or 1.9 additional days com-
pared to controls without AF (P < 0.0001). The estimated 1.4
million secondary AF discharges without cardiac predisposing
factors had an adjusted average inpatient cost of $8956, an
increase of $1908 compared to controls without AF or cardiac
predisposing factors (P < 0.0001). Secondary AF patients
without cardiac predisposing factors had an adjusted average
LOS of 6.2 days or one additional day compared to controls
(P < 0.0001). CONCLUSIONS: Inpatient costs and LOS were
signiﬁcantly higher for patients with a secondary AF discharge
diagnosis when compared to controls that did not have an AF
diagnosis. These differences, although still signiﬁcant, were less
pronounced among patients without cardiac predisposing
factors. Further research is warranted to investigate how second-
ary AF is most cost-effectively treated.
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OBJECTIVES: Atherothrombosis is the leading cause of death
worldwide with huge economic burden. Peripheral arterial
disease (PAD), a marker of disseminated vascular disease, puts
patients at a high risk of atherothrombotic events. The REACH
Registry is an international prospective registry of 67,888
patients from 44 countries at risk of atherothrombosis due to
coronary artery disease (CAD), cerebrovascular disease (CVD)
and/or PAD, or the presence of3 atherothrombotic risk factors.
PAD at enrollment was identiﬁed on the basis of current inter-
mittent claudication with either ankle brachial index (ABI) < 0.9,
or history of lower limb revascularization (angioplasty/stenting,
peripheral bypass graft) or amputation. METHODS: We
examined 2-year rates of vascular-related hospitalizations and
associated costs in 1303 REACH patients from Germany with
established PAD at baseline. Poisson regression was used to
identify independent predictors of vascular hospitalizations. The
costs per DRG for vascular hospitalizations were derived from
the German 2004 Case Fees Catalogue. RESULTS: At baseline,
mean age was 68 years, 29% female, 46% diabetes, 76% had
ABI < 0.9, 56% had prior lower limb revascularization, 13%
prior amputation, 63% had other involved vascular territories
(479 CAD + PAD; 136 CVD + PAD; 205 CAD + CVD + PAD).
There were 360 (28%) patients who had 1 vascular hospital-
izations at 2 years. Signiﬁcant (p < 0.05) independent baseline
predictors of an increased hospitalization rate included diabetes,
female, ABI < 0.9, prior peripheral revascularization, prior
amputation, CAD, hypertension, decreasing age and prior
smoking. Mean vascular hospitalization costs per patient were:
€2595 overall; €3052 female/€2423 male; €3351/€1973 with/
without diabetes; €2773/€2394 with/without prior lower limb
revascularization; €2787/€2578 with/without prior amputation.
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Vascular interventions account for 61% of hospitalization costs,
overall. CONCLUSIONS: Rates and costs of vascular events/
interventions are high in patients with PAD, and increase with
identiﬁable risk factors. Risk factor modiﬁcation and prevention
efforts are needed to lessen the burden of atherothrombotic
disease for PAD patients, and society.
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OBJECTIVES: To determinate the co-morbidity and direct costs
of stroke among Spanish population in daily medical practice.
METHODS: A retrospective study was performed based on data
from patients attended for stroke, aged >30 years, from ﬁve
Spanish primary care centres (PCC) and two hospitals in 2006.
Main analysed variables were: age, sex, general or speciﬁc
(cardiovascular and others) events/co-morbidities, use of drugs,
clinical parameters (according to NCEP-ATPIII) and direct costs
(pharmacy, derivations, visits, emergencies, procurement, and
hospitalisation). An ANCOVA analysis and logistic regression
were used to ﬁt the model. RESULTS: Of 57.026 patients
included in the analysis, 4.5% (n = 2.585, CI95%: 4.3–4.7%)
suffered stroke. The incidence of stroke was 220 new cases/
100.000 populations. Main differences between patients suffer-
ing stroke and control group were: age (72.5 vs. 53.5), men
(58.2% vs. 44.6%), events/year (7.9 vs. 4.8), visits/year (15.8 vs.
8.1), poli-pharmacy (91.5% vs. 53.6%), use of statins (85.0% vs.
32.2%), antiagregants and/or anticoagulants (78.9% vs. 28.0%),
p < 0.001 for all differences. Stroke had an independent relation
with age (odds ratio, [OR] = 1.4), male gender (OR = 2.3), dia-
betes (OR = 1.6), hypertension (OR = 1.5), smoking (OR = 1.5),
alcohol abuse (OR = 1.4), depression (OR = 1.4), dyslipidemia
(OR = 1.3) and dementia (OR = 1.2). Some of the results were:
systolic pressure (134.1 vs. 127.6 mmHg), body mass index
(28.9 vs. 27.9 kg/m2) and LDL-cholesterol (116.4 vs. 126.2 mg/
dl), in presence/absence of stroke, p < 0.001. The average of
annual costs of stroke was €2590.36 vs. €985.26, p < 0.001.
After the correction of the logistic model results did not change:
€1774.33 (IC: 1720.10-€1.828.55) vs. €1021.98 (IC: 1010.92-
€1033.03€, p < 0.001. All components of costs were higher in the
stroke group. CONCLUSIONS: Prevalence and incidence are
similar to that published in the literature. Patients that demanded
assistance for stroke had a higher number of co-morbidities and
a higher total cost/patient/year. Therapeutic objectives could be
improved, mainly in primary prevention of cardiovascular risk
factors.
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OBJECTIVES: Clopidogrel (in addition to aspirin) for the treat-
ment of all patients with acute coronary syndromes (ACS) was
recently approved for additional reimbursement under the Aus-
tralian Pharmaceutical Beneﬁts Scheme. We sought to estimate
the implications of this approval for the Australian health care
system. METHODS: A Markov model to determine cost-
effectiveness was constructed by extrapolation of data from the
Australian Acute Coronary Syndromes Prospective Audit
(ACACIA) registry (n = 2553) in the ﬁrst model cycle, and the
Reduction in Atherothrombosis for Continued Health
(REACH) registry (n = 2567) in subsequent model cycles. Efﬁ-
cacy data were drawn from the Clopidogrel in Unstable Angina
to Prevent Recurrent Events (CURE) trial. Drug, cardiovascular
disease and hospitalisation costs were sourced from the litera-
ture and health care reimbursement fees. These were updated as
required using Australian health price indices. An annual dis-
count rate of 5% was applied to all costs and effects beyond one
year in accordance with reimbursement guidelines. Data regard-
ing the prevalence of ACS was estimated from published
national Australian epidemiological and demographic data. As
clopidogrel is already reimbursed for patients who have taken
aspirin prior to their event, or who cannot take aspirin due to
allergy or intolerance, literature was reviewed to estimate this
population. RESULTS: The estimated number of newly eligible
patients ranged annually from 48,100 to 62,700 over ﬁve years.
The expanded treatment coverage was estimated to prevent an
additional 12,400 major cardiovascular events (comprising
myocardial infarctions, strokes and deaths) in the ﬁrst ﬁve
years, leading to a saving of A$175 million in health care costs
arising from avoided hospitalisation, procedures and medica-
tions. This has major resource implications for the Australian
health system in terms of stafﬁng, bed availability and emer-
gency admissions. CONCLUSIONS: The imminent implemen-
tation of unrestricted access to clopidogrel plus aspirin for all
ACS patients is likely to lead to signiﬁcant health and cost-
savings for Australia.
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OBJECTIVES: To determine the co-morbidity inﬂuence and the
direct cost according to cardiovascular risk levels (CRL) in
patients older than 55 years appertaining to population setting
and in clinical practice. METHODS: Multicentric design, real-
ized beginning from registers of subjects 55 years appertaining
to a seven centres of primary care (year 2006). The calculation of
the CRL was effected using Framingham-Wilson equation: low
risk (<10), moderate (10–19), high (20–29) and very high (30).
Main measures: general (age, gender, etc.), cardiovascular
co-morbidities (CIAP-2), cardiovascular events-CVE (criteria:
NCEP-ATP III), Charlson-index (patient severity) and cost
model. The general morbidity charge was measured beginning
from Adjusted-Clinical Groups (http://www.acg.jhph.edu).
Fixed/semiﬁxed costs were considered (structure, salary, services)
and variable ones (diagnostics/therapeutics requests, referrals,
drugs). An analysis of logistical regression and the covariance
(ANCOVA) was affected for the correction of the models
(procedure: Bonferroni), according to the recommendations of
Thompson-Barber. Program SPSSWIN; p < 0.05. RESULTS:
From 24,441 subjects older than 55 years, were attended 12,828.
The 30.1% (IC 95%: 29.3–30.9%) showed a high/very high
CRL. All studied variables in bivariant relation were related to
CRL. Increase of CRL was associated as an independent way to
man (OR = 7.1), diabetes (OR = 6.8), smoking (OR = 5.8),
hypertension (OR = 2.3), dislipemia (OR = 1.9), obesity
(OR = 1.4), CVE (OR = 1.3) and age (OR = 1.2), p < 0.001). The
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